Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.Leukemia. 2013; 27: 142-149
- Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.J Clin Oncol. 2012; 30: 980-988
- Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.Blood. 2014; 123: 3727-3732
- Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group.Blood. 2012; 120: 1581-1588
- Minimal residual disease in acute myeloid leukaemia.Nat Rev Clin Oncol. 2013; 10: 460-471
- Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.Blood. 2016; 127: 3165-3174
- Assessment of minimal residual disease in myeloma and the need for a consensus approach.Cytometry B Clin Cytom. 2016; 90: 21-25
- Predicting relapse risk in childhood acute lymphoblastic leukaemia.Br J Haematol. 2013; 162: 606-620
- Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.Cytometry B Clin Cytom. 2016; 90: 47-53
- Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities.Blood Rev. 2017; 31: 63-75
- A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.Leukemia. 1999; 13 (Available at:) (Accessed May 6, 2014): 558-567
- Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry.Blood. 2001; 98 (Available at:): 2498-2507
- Immunophenotypic analysis of hematogones (B-lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry.Leuk Lymphoma. 2004; 45 (Available at:) (Accessed May 6, 2014): 277-285
- Haematogones in the peripheral blood of adults: a four-colour flow cytometry study of 102 patients.Br J Haematol. 2004; 126: 209-212
- Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.Am J Clin Pathol. 2009; 132: 940-949
- B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model.Am J Clin Pathol. 2015; 143: 716-724
- B-cell precursor bone marrow reconstitution after bone marrow transplantation.Am J Clin Pathol. 1994; 102 (Available at:): 231-236
- Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease.Br J Haematol. 2000; 110 (Available at:): 139-146
- Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children’s oncology group.Cytometry B Clin Cytom. 2005; 68: 18-24
- Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.Leukemia. 2005; 19: 49-56
- Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience.Am J Clin Pathol. 2007; 127: 39-46
- Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.Cytometry B Clin Cytom. 2008; 74: 150-155
- Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.Cytometry B Clin Cytom. 2010; 78: 147-153
- Flow cytometric monitoring of residual disease in acute leukemia.Methods Mol Biol. 2013; 999: 123-136
- A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Leukemia. 2016; 30: 929-936
- Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.Blood. 2017; 129: 347-357
- Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study.Leukemia. 2003; 17: 1566-1572
- Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.Cytometry B Clin Cytom. 2013; 84: 359-369
- Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.Am J Clin Pathol. 2009; 132: 692-698
- Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry.Leuk Lymphoma. 1994; 13: 87-90
- Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.Lancet. 1998; 351: 550-554
- Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.Blood. 2002; 100: 2399-2402
- Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.Blood. 2002; 99 (Available at:): 1952-1958
- Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.Leukemia. 2003; 17: 138-148
- Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.Blood. 2002; 100: 52-58
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study.Blood. 2008; 111: 5477-5485
- Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children’s Oncology Group trial P9906.Pediatr Blood Cancer. 2011; 57: 569-577
- Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232.Blood. 2015; 126: 964-971
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.Leukemia. 2004; 18: 499-504
- Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children’s Oncology Group Study.J Clin Oncol. 2008; 26: 3971-3978
- Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Lancet Oncol. 2015; 16: 465-474
- Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels.Blood. 2015; 126: 2896-2899
- High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Blood. 2011; 118: 223-230
- Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.Ann Hematol. 2012; 91: 183-192
- Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Blood. 2012; 120: 468-472
- Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA.J Clin Oncol. 2014; 32: 1595-1604
- Experience with MRD testing in B-ALL by flow cytometry does not prevent interpretative discordance.Blood. 2016; 128: 2907
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med. 2014; 371: 1507-1517
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.Blood. 2015; 125: 4017-4023
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Lancet Oncol. 2015; 16: 57-66
- Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.Blood. 2015; 126: 2578-2584
- Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies.Cancer. 2016; 122: 2178-2185
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet. 2015; 385: 517-528
- Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med. 2014; 6: 224ra25
- Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.J Clin Oncol. 2014; 32: 4134-4140
- A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.Cytometry B Clin Cytom. 2016; https://doi.org/10.1002/cyto.b.21482
Article info
Publication history
Published online: August 30, 2017
Footnotes
Disclosure Statement: The authors have nothing to disclose.
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
